Linking Ciltacabtagene Autoleucel to Immune Effector Cell-Associated Enterocolitis

Overview

Analysis of the FDA Adverse Event Reporting System (FAERS) identified immune-mediated enterocolitis exclusively associated with ciltacabtagene autoleucel among FDA-approved CAR T-cell therapies. This adverse event appears to be a delayed, organ-specific toxicity linked to CAR T-cell infiltration of gut mucosa, with a strong signal detected (ROR 83.65).

Background

Chimeric antigen receptor (CAR) T-cell therapies have transformed treatment for multiple myeloma but are associated with immune-mediated toxicities such as cytokine release syndrome (CRS) and neurotoxicity (ICANS). Immune effector cell-associated enterocolitis (IEC-EC) is a recently described, rare toxicity characterized by severe non-bloody diarrhea and gut inflammation occurring weeks to months post-infusion. The FDA issued warnings regarding IEC-EC risk after ciltacabtagene autoleucel treatment, prompting investigation into its epidemiology and pathophysiology. Understanding whether IEC-EC is linked to specific CAR T constructs or disease factors is critical for patient management.

Data Highlights

Key Findings

• Only ciltacabtagene autoleucel showed significant reports of immune-mediated enterocolitis in FAERS, with 31 cases and a high ROR of 83.65.
• Other CAR T-cell products, including idecabtagene vicleucel, had no reported IEC-EC cases in the database despite known clinical use.
• IEC-EC pathology involves CAR T-cell infiltration into gut mucosa causing mucosal injury resembling graft-versus-host disease.
• Potential mechanisms include persistent CAR T-cell activation, cytokine-mediated inflammation, and off-tumor on-target effects against BCMA-expressing gut cells.
• Differences in scFv binding domains and avidity between ciltacabtagene autoleucel and idecabtagene vicleucel may explain the differential IEC-EC risk.
• FAERS data are limited by underreporting and lack of demographic details, thus serving as hypothesis-generating rather than definitive incidence evidence.

Clinical Implications

Clinicians should be vigilant for delayed onset enterocolitis symptoms in patients treated with ciltacabtagene autoleucel. Early recognition and management with systemic corticosteroids may be warranted given the organ-specific immune toxicity. Understanding construct-specific risks can guide monitoring strategies and inform patient counseling about potential adverse events.

Conclusion

Immune effector cell-associated enterocolitis is a rare but serious toxicity predominantly linked to ciltacabtagene autoleucel therapy. Further research is needed to elucidate mechanisms, validate biomarkers, and optimize management of this emerging complication.

References

1. Fortuna et al. 2023 -- Immune Effector Cell-Associated Enterocolitis Following CAR T-Cell Therapy
2. FDA Adverse Event Reporting System (FAERS) Data Analysis 2013-2025
3. Immunopathology and Mechanisms of IEC-EC in CAR T-cell Therapy 2024